市場調查報告書

代謝性疾病治療藥市場規模,佔有率,趨勢分析報告:給藥途徑,各疾病(糖尿病,溶小體異常),治療類別,各地區,市場區隔預測

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 - 2025

出版商 Grand View Research, Inc. 商品編碼 786006
出版日期 內容資訊 英文 145 Pages
商品交期: 2-3個工作天內
價格
代謝性疾病治療藥市場規模,佔有率,趨勢分析報告:給藥途徑,各疾病(糖尿病,溶小體異常),治療類別,各地區,市場區隔預測 Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration, By Disease (Diabetes, Lysosomal Disorders), By Therapy Type, By Region, and Segment Forecasts, 2019 - 2025
出版日期: 2019年01月17日內容資訊: 英文 145 Pages
簡介

本報告提供全球代謝性疾病治療藥市場相關調查,彙整市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊。

第1章 調查方法與範圍

第2章 摘要整理

第3章 市場變數,趨勢,範圍

  • 市場區隔和範圍
    • 推動市場的要素分析
    • 阻礙市場的要素分析
  • 滲透度與成長預測製圖
  • SWOT分析
  • 產業分析

第4章 各疾病預測與趨勢分析

  • 趨勢分析
  • 溶小體貯存障礙
  • 糖尿病
  • 肥胖
  • 遺傳性代謝性疾病
  • 高膽固醇症

第5章 治療類別預測與趨勢分析

  • 趨勢分析
  • 酵素置換雙方
  • 細胞移植
  • 小分子治療
  • 基材降低雙方
  • 基因治療
  • 藥物治療

第6章 各給藥途徑預測與趨勢分析

  • 趨勢分析
  • 口服給藥
  • 非口服給藥
  • 其他

第7章 各地區預測

  • 市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第8章 競爭環境

  • 策略架構
  • 市場進入分類
  • 企業簡介
    • Novo Nordisk
    • Eli Lilly and Company
    • Shire Plc
    • Sanofi
    • Merck KgaA
    • AstraZeneca
    • AbbVie Inc.,
    • Actelion Pharmaceuticals Ltd
    • Amgen Inc.,
    • Biocon
    • BioMarin
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Cipla Inc.,
    • CymaBay Therapeutics
目錄
Product Code: GVR-3-68038-011-8

The global metabolic disorder therapeutics market size is expected to reach USD 88.93 billion by 2025, according to a new report by Grand View Research, Inc. The market is anticipated to witness a CAGR of 7.56% during the estimated period. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.

Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.

Further key findings from the study suggest:

Diabetes segment led the market in 2017, in terms of revenue generation,owing to higher prevalence and drug usage

Obesity segment is expected to register a CAGR of 9.27% over the forecast period owing to increasing prevalence as a result of sedentary lifestyle changes

Drug therapy was the most-preferred therapy due to its high reliability proven success and availability of various types of drugs to treat metabolic diseases

The segment is expected to maintain its dominance even during the forecast years due to the introduction of smart technology to deliver antidiabetic drug on a regulated basis

Key companies in this market are Novo Nordisk A/S;Sanofi S.A.; BoehringerIngelheim GmbH; Eli Lilly and Company; Merck KgaA; Amgen, Inc.; AstraZeneca PLC; Actelion Pharmaceuticals Ltd.; Shire PLC; AbbVie, Inc.;Biocon Ltd.;BioMarinPharmaceutical, Inc.; Bristol-Myers Squibb Company; Cipla, Inc.; and CymaBay Therapeutics, Inc.

Most of these companies are focusing on strategies, such as collaborations, expansion of product portfolios, and M&A to maintain their industry position

Oral route of administration was the key revenue-generating segment in 2017owing to its benefits, such as high reliability and ease of administration

North America was the largest regional market in 2017 and will maintain the trend in future due to the presence of key companies and rising cases of diabetes and obesity

Table of Contents

Chapter 1 Research Methodology & Scope

  • 1.1 Information Procurement
    • 1.1.1 Purchased database:
    • 1.1.2 GVR's internal database
  • 1.2 Research Methodology
  • 1.3 Geographic scope & assumptions
  • 1.4 Region-wise market calculation
    • 1.4.1 Region-wise market: Base estimates
    • 1.4.2 Global market: CAGR calculation
  • 1.5 Region-based segment share calculation
  • 1.6 List of Secondary Sources

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
    • 3.1.1 Market Driver Analysis
      • 3.1.1.1 Increasing prevalence of metabolic disorders
      • 3.1.1.2 Collaborations between manufacturers and research facilities
      • 3.1.1.3 Government initiatives
    • 3.1.2 Market restraint analysis
      • 3.1.2.1 Expensive rare disease therapies
      • 3.1.2.2 Ambiguous regulatory policies
  • 3.2 Penetration & growth prospect mapping
  • 3.3 Metabolic Disorder Therapeutics - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.4 Industry Analysis - Porter's

Chapter 4 Metabolic Disorder Therapeutics Market: Disease Estimates & Trend Analysis

  • 4.1 Metabolic Disorder Therapeutics Market by Disease, Movement Analysis
  • 4.2 Lysosomal Storage Diseases
    • 4.2.1 Lysosomal storage diseases market estimates and forecast, 2014 - 2025 (USD Billion)
    • 4.2.2 Gaucher's Disease
      • 4.2.2.1 Gaucher's disease market estimates and forecast, 2014 - 2025 (USD Billion)
    • 4.2.3 Metachromatic leukodystrophy
      • 4.2.3.1 Metachromatic leukodystrophy market estimates and forecast, 2014 - 2025 (USD Billion)
    • 4.2.4 Hurler - Scheie Disease
      • 4.2.4.1 Hurler - Scheie disease market estimates and forecast, 2014 - 2025 (USD Billion)
    • 4.2.5 Sanfilipo A disease
      • 4.2.5.1 Sanfilipo A disease market estimates and forecast, 2014 - 2025 (USD Billion)
    • 4.2.6 Other diseases
      • 4.2.6.1 Others diseases market estimates and forecast, 2014 - 2025 (USD Billion)
  • 4.3 Diabetes
    • 4.3.1 Diabetes market estimates and forecast, 2014 - 2025 (USD Billion)
  • 4.4 Obesity
    • 4.4.1 Obesity market estimates and forecast, 2014 - 2025 (USD Billion)
  • 4.5 Inherited Metabolic Disorders
    • 4.5.1 Inherited metabolic disorders market estimates and forecast, 2014 - 2025 (USD Billion)
  • 4.6 Hypercholesterolemia
    • 4.6.1 Hypercholesterolemia market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 5 Metabolic Disorder Therapeutics Market: Therapy Type Estimates & Trend Analysis

  • 5.1 Metabolic Disorder Therapeutics Market: Therapy Type Movement Analysis
  • 5.2 Enzyme Replacement Therapy
    • 5.2.1 Enzyme replacement therapy market estimates and forecast, 2014 - 2025 (USD Billion)
  • 5.3 Cellular Transplantation
    • 5.3.1 Cellular transplantation market estimates and forecast, 2014 - 2025 (USD Billion)
  • 5.4 Small Molecule-Based Therapy
    • 5.4.1 Small molecule based therapy market estimates and forecast, 2014 - 2025 (USD Billion)
  • 5.5 Substrate Reduction Therapy
    • 5.5.1 Substrate reduction therapy market estimates and forecast, 2014 - 2025 (USD Billion)
  • 5.6 Gene Therapy
    • 5.6.1 Gene therapy market estimates and forecast, 2014 - 2025 (USD Billion)
  • 5.7 Drug Therapy
    • 5.7.1 Drug therapy market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 6 Metabolic Disorder Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 6.1 Metabolic Disorder Therapeutics market: route of administration movement analysis
  • 6.2 Oral Administration
    • 6.2.1 Oral administration market estimates and forecast, 2014 - 2025 (USD Billion)
  • 6.3 Parenteral Administration
    • 6.3.1 Parenteral administration market estimates and forecast, 2014 - 2025 (USD Billion)
  • 6.4 Other route of administration
    • 6.4.1 Other route of administration market estimates and forecast, 2014 - 2025 (USD Billion)

Chapter 7 Metabolic Disorder Therapeutics Market: Regional Outlook

  • 7.1 Metabolic Disorder Therapeuticsmarket share by region, 2017 & 2025 (USD Billion)
  • 7.2 North America
    • 7.2.1 North America market estimates and forecast, 2014 - 2025 (USD Billion)
    • 7.2.2 U.S
      • 7.2.2.1 U.S metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.2.3 Canada
      • 7.2.3.1 Canada metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • 7.3 Europe
    • 7.3.1 Europe metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.3.2 Germany
      • 7.3.2.1 Germany metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.3.3 U.K.
      • 7.3.3.1 U.K. metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.4.2 Japan
      • 7.4.2.1 Japan metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.4.3 China
      • 7.4.3.1 China metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • 7.5 Latin America
    • 7.5.1 Latin America metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • 7.6 MEA
    • 7.6.1 MEA metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)

Chapter 8 Competitive Landscape

  • 8.1 Strategy Framework
  • 8.2 Market Participation Categorization
  • 8.3 Company Profiles
    • 8.3.1 Novo Nordisk
      • 8.3.1.1 Company overview
      • 8.3.1.2 Financial performance
      • 8.3.1.3 Product benchmarking
      • 8.3.1.4 Strategic initiatives
    • 8.3.2 Eli Lilly and Company
      • 8.3.2.1 Company overview
      • 8.3.2.2 Financial Performance
      • 8.3.2.3 Product benchmarking
      • 8.3.2.4 Strategic initiatives
    • 8.3.3 Shire Plc
      • 8.3.3.1 Company overview
      • 8.3.3.2 Financial performance
      • 8.3.3.3 Product benchmarking
      • 8.3.3.4 Strategic initiatives
    • 8.3.4 Sanofi
      • 8.3.4.1 Company overview
      • 8.3.4.2 Financial performance
      • 8.3.4.3 Product benchmarking
      • 8.3.4.4 Strategic initiatives
    • 8.3.5 Merck KgaA
      • 8.3.5.1 Company overview
      • 8.3.5.2 Financial performance
      • 8.3.5.3 Product benchmarking
      • 8.3.5.4 Strategic initiatives
    • 8.3.6 AstraZeneca
      • 8.3.6.1 Company overview
      • 8.3.6.2 Financial performance
      • 8.3.6.3 Product benchmarking
      • 8.3.6.4 Strategic initiatives
    • 8.3.7 AbbVie Inc.,
      • 8.3.7.1 Company overview
      • 8.3.7.2 Financial performance
      • 8.3.7.3 Product benchmarking
      • 8.3.7.4 Strategic initiatives
    • 8.3.8 Actelion Pharmaceuticals Ltd
      • 8.3.8.1 Company overview
      • 8.3.8.2 Financial performance
      • 8.3.8.3 Product benchmarking
      • 8.3.8.4 Strategic initiatives
    • 8.3.9 Amgen Inc.,
      • 8.3.9.1 Company overview
      • 8.3.9.2 Financial performance
      • 8.3.9.3 Product benchmarking
      • 8.3.9.4 Strategic initiatives
    • 8.3.10 Biocon
      • 8.3.10.1 Company overview
      • 8.3.10.2 Financial performance
      • 8.3.10.3 Product benchmarking
      • 8.3.10.4 Strategic initiatives
    • 8.3.11 BioMarin
      • 8.3.11.1 Company overview
      • 8.3.11.2 Financial performance
      • 8.3.11.3 Product benchmarking
      • 8.3.11.4 Strategic initiatives
    • 8.3.12 Boehringer Ingelheim
      • 8.3.12.1 Company overview
      • 8.3.12.2 Financial performance
      • 8.3.12.3 Product benchmarking
      • 8.3.12.4 Strategic initiatives
    • 8.3.13 Bristol-Myers Squibb
      • 8.3.13.1 Company overview
      • 8.3.13.2 Financial performance
      • 8.3.13.3 Product benchmarking
      • 8.3.13.4 Strategic initiatives
    • 8.3.14 Cipla Inc.,
      • 8.3.14.1 Company overview
      • 8.3.14.2 Financial performance
      • 8.3.14.3 Product benchmarking
      • 8.3.14.4 Strategic initiatives
    • 8.3.15 CymaBay Therapeutics
      • 8.3.15.1 Company overview
      • 8.3.15.2 Financial performance
      • 8.3.15.3 Product benchmarking
      • 8.3.15.4 Strategic Initiatives

List of Tables

  • TABLE 1 Country share estimation
  • TABLE 2 North America metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 3 North America metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 4 North America metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 5 North America metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 6 U.S. metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 7 U.S. metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 8 U.S. metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 9 U.S. metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 10 Canada metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 11 Canada metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 12 Canada metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 13 Canada metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 14 Europe metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 15 Europe metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 16 Europe metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 17 Europe metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 18 Germany metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 19 Germany metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 20 Germany metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 21 Germany metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 22 U.K. metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 23 U.K. metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 24 U.K. metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 25 U.K. metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 26 Asia Pacific metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 27 Asia Pacific metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 28 Asia Pacific metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 29 Asia Pacific metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 30 Japan metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 31 Japan metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 32 Japan metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 33 Japan metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 34 China metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 35 China metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 36 China metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 37 China metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 38 Latin America metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 39 Latin America metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 40 Latin America metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 41 Latin America metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 42 Brazil metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 43 Brazil metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 44 Brazil metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 45 Brazil metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 46 MEA metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 47 MEA metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 48 MEA metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 49 MEA metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)
  • TABLE 50 South Africa metabolic disorder therapeutics market, by disease scope, 2014 - 2025 (USD Billion)
  • TABLE 51 South Africa metabolic disorder therapeutics market estimates and forecasts, by lysosomal leukodystrophy, 2014 - 2025 (USD Billion)
  • TABLE 52 South Africa metabolic disorder therapeutics market estimates and forecasts, by Therapy, 2014 - 2025 (USD Billion)
  • TABLE 53 South Africa metabolic disorder therapeutics market estimates and forecasts, by route of administration, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Value chain based sizing & forecasting
  • FIG. 4 QFD modelling for market share assessment
  • FIG. 5 Market summary
  • FIG. 6 Market trends & outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market driver relevance analysis (Current & future impact)
  • FIG. 9 Market restraint relevance analysis (Current & future impact)
  • FIG. 10 Penetration & growth prospect mapping
  • FIG. 11 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 12 Porter's Five Forces Analysis
  • FIG. 13 Metabolic disorder therapeutics market disease outlook
  • FIG. 14 Metabolic disorder therapeutics market: Disease movement analysis
  • FIG. 15 Global Lysosomal Storage Diseases market, 2014 - 2025 (USD Billion)
  • FIG. 16 Gaucher's disease market, 2014 - 2025 (USD Billion)
  • FIG. 17 Global metachromatic leukodystrophy market, 2014 - 2025 (USD Billion)
  • FIG. 18 Hurler - Scheie disease market estimates and forecast, 2014 - 2025 (USD Billion)
  • FIG. 19 Global Sanfilipo A market estimates and forecast, 2014 - 2025 (USD Billion)
  • FIG. 20 Other diseases market estimates and forecast, 2014 - 2025 (USD Billion)
  • FIG. 21 Global diabetes market, 2014 - 2025 (USD Billion)
  • FIG. 22 Global obesity market, 2014 - 2025 (USD Billion)
  • FIG. 23 Inherited metabolic disorders market, 2014 - 2025 (USD Billion)
  • FIG. 24 Hypercholesterolemia market, 2014 - 2025 (USD Billion)
  • FIG. 25 Metabolic disorder therapeutics market therapy type outlook key takeaways
  • FIG. 26 Metabolic disorder therapeutics market: therapy movement analysis
  • FIG. 27 Global enzyme replacement therapy animals market, 2014 - 2025 (USD Billion)
  • FIG. 28 Global cellular transplantation market, 2014 - 2025 (USD Billion)
  • FIG. 29 Global small molecule based therapy market, 2014 - 2025 (USD Billion)
  • FIG. 30 Global substrate reduction therapy market, 2014 - 2025 (USD Billion)
  • FIG. 31 Global gene therapy market, 2014 - 2025 (USD Billion)
  • FIG. 32 Drug therapy market, 2014 - 2025 (USD Billion)
  • FIG. 33 Metabolic disorder therapeutics market route of administration outlook key takeaways
  • FIG. 34 Metabolic Disorder Therapeutics market: route of administration movement analysis
  • FIG. 35 Global oral administration market, 2014 - 2025 (USD Billion)
  • FIG. 36 Global parenteral administration market, 2014 - 2025 (USD Billion)
  • FIG. 37 Global other route of administration market, 2014 - 2025 (USD Billion)
  • FIG. 38 Regional market place: Key takeaways
  • FIG. 39 Regional outlook, 2016 & 2025
  • FIG. 40 North America metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 41 U.S. metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 42 Canada metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 43 Europe metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 44 Germany metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 45 U.K. metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 46 Asia Pacific metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 47 Japan metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 48 China metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 49 Latin America metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 50 Brazil metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 51 MEA metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)
  • FIG. 52 South Africa metabolic disorder therapeutics market, 2014 - 2025 (USD Billion)